|
1
|
Akinbo DB and Ajayi OI: Thrombotic
pathogenesis and laboratory diagnosis in cancer patients, an
update. Int J Gen Med. 16:259–272. 2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Benedetti M, Morroni S, Fiaschini P, Coiro
S and Savino K: Nonbacterial thrombotic endocarditis with multiple
systemic emboli in a patient with primary lung cancer. J Cardiovasc
Echogr. 32:129–131. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Scalia GM, Tandon AK and Robertson JA:
Stroke, aortic vegetations and disseminated adenocarcinoma-a case
of marantic endocarditis. Heart Lung Circ. 21:234–236.
2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Soga Y, Taira K, Sugimoto A, Kurosawa M,
Kira H, Su T, Doi K, Nakano A and Himura Y: Mitral valve
nonbacterial thrombotic endocarditis: A rare multi-surgery-tolerant
survivor of Trousseau's syndrome. Surg Case Rep.
4(104)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moik F and Ay C: Venous and arterial
thromboembolism in patients with cancer treated with targeted
anti-cancer therapies. Thromb Res. 213 (Suppl 1):S58–S65.
2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cheng Y, Ouyang W, Jie C, Zhang J, Yu J
and Xie C: A case of late and lethal Trousseau's syndrome induced
by pembrolizumab in lung adenocarcinoma. Immunotherapy. 15:71–75.
2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhao L, Zheng H, Zhu L and Jiang P:
Trousseau's syndrome in a non-small cell lung cancer patient
aggravated by pembrolizumab. J Oncol Pharm Pract. 29:233–238.
2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shionoya Y, Hirohashi Y, Takahashi H,
Hashimoto M, Nishiyama K, Takakuwa Y, Nakatsugawa M, Kubo T,
Kanaseki T, Tsukahara T and Torigoe T: Possible pseudo-progression
of non-small cell lung carcinoma in a patient with clinical
hyper-progression associated with trousseau syndrome who was
treated with pembrolizumab: A case report. Anticancer Res.
41:3699–3706. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Horio Y, Takamatsu K, Tamanoi D, Sato R,
Saruwatari K, Ikeda T, Nakane S, Nakajima M, Saeki S, Ichiyasu H,
et al: Trousseau's syndrome triggered by an immune checkpoint
blockade in a non-small cell lung cancer patient. Eur J Immunol.
48:1764–1767. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ogata M, Ama Y, Ogata T, Hirabatake M,
Yasui H and Satake H: Direct oral anticoagulants for the treatment
of venous thromboembolism in patients with active cancer. In Vivo.
35:2747–2753. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Samaranayake CB, Anderson J, McCabe C,
Zahir SF, Upham JW and Keir G: Direct oral anticoagulants for
cancer-associated venous thromboembolisms: A systematic review and
network meta-analysis. Intern Med J. 52:272–281. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Frere C, Farge D, Schrag D, Prata PH and
Connors JM: Direct oral anticoagulant versus low molecular weight
heparin for the treatment of cancer-associated venous
thromboembolism: 2022 updated systematic review and meta-analysis
of randomized controlled trials. J Hematol Oncol.
15(69)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cohen JV, Alomari AK, Vortmeyer AO,
Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL and Kluger HM:
Melanoma brain metastasis pseudoprogression after pembrolizumab
treatment. Cancer Immunol Res. 4:179–182. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Vander Jagt TA, Davis LE, Thakur MD, Franz
C and Pollock JM: Pseudoprogression of CNS metastatic disease of
alveolar soft part sarcoma during anti-PDL1 treatment. Radiol Case
Rep. 13:882–885. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Urban H, Steidl E, Hattingen E, Filipski
K, Meissner M, Sebastian M, Koch A, Strzelczyk A, Forster MT,
Baumgarten P, et al: Immune Checkpoint inhibitor-induced cerebral
pseudoprogression: patterns and categorization. Front Immunol.
12(798811)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tanimura J, Yamamoto T and Hashimoto T:
Clinical features and prognostic factors in patients with
cancer-associated multiple ischemic stroke: A retrospective
observational study. J Stroke Cerebrovasc Dis.
31(106813)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Riaz IB, Fuentes HE, Naqvi SAA, He H,
Sipra QR, Tafur AJ, Padranos L, Wysokinski WE, Marshall AL, Vandvik
PO, et al: Direct oral anticoagulants compared with dalteparin for
treatment of cancer-associated thrombosis: A living, interactive
systematic review and network meta-analysis. Mayo Clin Proc.
97:308–324. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tachihara M, Nikaido T, Wang X, Sato Y,
Ishii T, Saito K, Sekine S, Tanino Y, Ishida T and Munakata M: Four
cases of Trousseau's syndrome associated with lung adenocarcinoma.
Intern Med. 51:1099–1102. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nonagase Y, Takeda M, Tanaka K, Hayashi H,
Iwasa T and Nakagawa K: Treatment of EGFR mutation-positive
non-small cell lung cancer complicated by Trousseau syndrome with
gefitinib followed by osimertinib: A case report. Oncotarget.
9:29532–29535. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ortega MA, Navarro F, Pekarek L,
Fraile-Martínez O, García-Montero C, Saez MA, Arroyo M, Monserrat J
and Alvarez-Mon M: Exploring histopathological and serum biomarkers
in lung adenocarcinoma: Clinical applications and translational
opportunities (review). Int J Oncol. 61(154)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ortega MA, Pekarek L, Navarro F,
Fraile-Martínez O, García-Montero C, Álvarez-Mon MÁ, Diez-Pedrero
R, Boyano-Adánez MDC, Guijarro LG, Barrena-Blázquez S, et al:
Updated views in targeted therapy in the patient with non-small
cell lung cancer. J Pers Med. 13(167)2023.PubMed/NCBI View Article : Google Scholar
|
